NEW YORK (GenomeWeb News) – DNA sequencing technologies startup GenapSys has raised $8.5 million of a target goal of $13.6 million, the company disclosed in a document recently filed with the US Securities and Exchange Commission.

The company said in its Form D that the amount raised is in the form of equity, and 11 investors participated in the raise.

Hesaam Esfandyarpour, GenapSys' founder and CEO, did not respond to requests seeking comment and it is unclear who the participants are in the private financing round. It also is unclear how the funds will be used.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.